FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* EMSTER KURT VON				<u>C</u>	2. Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]								tionship of Reporting all applicable) Director		Person(s) to Issuer		
(Last)	(First)	(1)	/liddle)		3. Date of Earliest Transaction (Month/Day/Year) 01/25/2023								Officer (give title below)			Other (s below)	pecify
C/O CYMABAY THERAPEUTICS, INC. 7575 GATEWAY BLVD., SUITE 110				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							- 1	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) NEWARK	CA	9	4560										Form file	d by More ti	han O	ne Reportino	g Person
(City)	(State) (Z	Zip)														
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date						2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr.		rities Acquired (A) or ed Of (D) (Instr. 3, 4 and 5)		5. Amount Securities Beneficially Following	y Owned or I Reported (Ins		Direct (D) lirect (I) 4)	7. Nature of Indirect Beneficial Ownership	
								Code	/ Am	ount	ount (A) or (D)		Transactio (Instr. 3 and				(Instr. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (I	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expira Date	ition	Title	Amount or Number of Shares		(Instr. 4)	ni(s)		
Stock Option (right to buy)	\$7.8	01/25/2023		A		25,000		(1)	01/24/	2033	Common Stock	25,000	\$0	25,000		D	

Explanation of Responses:

1. The option vests as to 1/12 of the underlying shares monthly from January 1, 2023.

/s/ Sujah Shah, as attorney-in-fact for Kurt von Emster 01/26/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.